3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Dermatologic
3
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fluorouracil
616
Oxaliplatin
579
Gemcitabine
492
Capecitabine
445
Leucovorin
427
Irinotecan
390
Bevacizumab
330
Cisplatin
320
Radiotherapy
245
Cetuximab
215
Sorafenib
167
pembrolizumab
152
Docetaxel
150
Paclitaxel
140
Nivolumab
128
Albumin-Bound Paclitaxel
108
130-nm albumin-bound paclitaxel
108
Folfox protocol
101
Panitumumab
95
Erlotinib Hydrochloride
95
Surgical Procedures, Operative
86
regorafenib
84
S 1 (combination)
81
Drug Therapy
80
Radiation
69
Carboplatin
65
Neoadjuvant Therapy
64
Colonoscopy
64
Radiosurgery
63
Surveys and Questionnaires
60
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
bempegaldesleukin
×
Gastrointestinal
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts